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ABSTRACT: Ipomoeassin F is a potent natural cytotoxin that
inhibits growth of many tumor cell lines with single-digit nanomolar
potency. However, its biological and pharmacological properties have
remained largely unexplored. Building upon our earlier achievements
in total synthesis and medicinal chemistry, we used chemical
proteomics to identify Sec61α (protein transport protein Sec61
subunit alpha isoform 1), the pore-forming subunit of the Sec61
protein translocon, as a direct binding partner of ipomoeassin F in
living cells. The interaction is speciﬁc and strong enough to survive
lysis conditions, enabling a biotin analogue of ipomoeassin F to pull
down Sec61α from live cells, yet it is also reversible, as judged by
several experiments including ﬂuorescent streptavidin staining, delayed competition in aﬃnity pulldown, and inhibition of TNF
biogenesis after washout. Sec61α forms the central subunit of the ER protein translocation complex, and the binding of
ipomoeassin F results in a substantial, yet selective, inhibition of protein translocation in vitro and a broad ranging inhibition of
protein secretion in live cells. Lastly, the unique resistance proﬁle demonstrated by speciﬁc amino acid single-point mutations in
Sec61α provides compelling evidence that Sec61α is the primary molecular target of ipomoeassin F and strongly suggests that
the binding of this natural product to Sec61α is distinctive. Therefore, ipomoeassin F represents the ﬁrst plant-derived,
carbohydrate-based member of a novel structural class that oﬀers new opportunities to explore Sec61α function and to further
investigate its potential as a therapeutic target for drug discovery.
■ INTRODUCTION
Historically, natural products have signiﬁcantly contributed to
the development of drugs for human disorders,1 most notably as
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anticancer chemotherapeutics.2 Structurally and functionally
unique natural products also provide a spectrum of valuable
chemical tools for examining biological systems in translational
biomedical research.3,4 To continue our battle against various
unsolved problems of human health, including those arising
from drug resistance, it is crucial to systematically investigate
underexplored areas of existing chemical space such as those
oﬀered by bioactive natural products with unique structures
and/or mechanisms.5
Resin glycosides, also called glycoresins, are a large collection
of amphiphilic glycolipids isolated from the morning glory
family of plants,6 and these compounds are considered active
ingredients of many morning glory-based traditional medicines
that are used worldwide. Resin glycosides consist of a diﬀerently
acylated oligosaccharide glycosylated with amono- or dihydroxy
C14 or C16 fatty acid, with more than 300 family members
discovered to date. Through an ester bond, the fatty acid chain is
usually folded back to form a macrolactone ring of various sizes
spanning one or more carbohydrate units. Because of their
unique macrocyclic architecture with embedded carbohydrates
and their broad spectrum of biological activities exhibited in
phenotypic screens, resin glycosides have attracted considerable
attention from the synthetic chemistry community, but not
much beyond.7−9
In 2005, a new family of glycoresins, ipomoeassins A−E, was
isolated from the leaves of Ipomoea squamosa found in the
Suriname rainforest and shown to inhibit the proliferation of
A2780 human ovarian cancer cells.10 Among these compounds,
ipomoeassin D (Figure 1) displayed the greatest potency, with
an IC50 value of 35 nM. Two years later, a new member of the
family, ipomoeassin F (Figure 1), was isolated and showed a
cytotoxicity comparable to ipomoeassin D.11 Because of their
promising antiproliferative activity and unique molecular
skeleton with carbohydrates being part of the macrocycle,
these newly discovered natural glycoconjugates quickly inspired
synthetic chemists, including ourselves, to tackle their total
syntheses.12−16 Subsequently, ipomoeassin F was conﬁrmed to
be the most cytotoxic resin glycoside discovered to date with
single-digit nanomolar IC50 values against several cancer-derived
cell lines.13 Intriguingly, ipomoeassins A and F (see Figure 1)
have distinct cytotoxicity proﬁles, as revealed in the NCI 60-cell-
line screen, suggesting that the ipomoeassins may possess an
unusual mode of action.16,17 On this basis, ipomoeassin F is a
very promising candidate for molecular probe and even
chemotherapeutic development; however, the absence of
knowledge about the cellular targets of ipomoeassin F has
signiﬁcantly impeded such eﬀorts. To overcome this challenge,
after improving our understanding of the structure−activity
relationship (SAR) of ipomoeassin F through medicinal
chemistry studies,18−20 we employed a chemical proteomics
approach to identify its binding partner(s) in human cells. Here
we describe the evolution of our chemoproteomic studies that
enabled the discovery of Sec61α (protein transport protein
Sec61 subunit alpha isoform 1) as a primary molecular target of
ipomoeassin F and our subsequent mechanistic investigations
that validate this component as a key target mediating
cytotoxicity. To this end, we compared the activity of
ipomoeassin F to mycolactone, a recently discovered broad-
spectrum inhibitor of Sec61-dependent translocation.21,22 This
polyketide lactone is the pathogenic exotoxin of Buruli ulcer
disease (Mycobacterium ulcerans infection) that has well-
established immunosuppressive and cytotoxic activities.23,24
We deﬁne the inhibitory eﬀects of ipomoeassin F on Sec61-
mediated protein translocation into and across the membrane of
the endoplasmic reticulum (ER), corroborating our contempo-
raneous observations of the potent inhibition of cellular protein
secretion by ipomoeassin F.
■ RESULTS AND DISCUSSION
Design, Synthesis, and Proteomic Evaluation of
Chemical Probes Derived from Ipomoeassin F. Michael
acceptor systems are present in many electrophilic natural
products, allowing the formation of covalent adducts with bio-
macromolecules, which are often responsible for their biological
activities.25 Because of signiﬁcant activity loss (up to 160-fold)
after reducing one of the two double bonds in the α,β-
unsaturated esters to a single bond,18 we hypothesized that the
cinnamate and/or the tiglate (Figure 1) may enable irreversible
binding between ipomoeassin F and its biological target(s).
Therefore, we initially designed and synthesized a potential
activity-based probe,26−28 3 (Scheme 1), by introducing a small
propargyloxy group to the para-position of the benzene ring.
Probe 3 was synthesized in two steps from key intermediate 1
obtained during the total synthesis of ipomoeassin F.15 The
alkyne-functionalized cinnamic acid 2 was synthesized as
previously described.29 N,N′-Dicyclohexylcarbodiimide
(DCC)-mediated Steglich esteriﬁcation was applied to couple
1 with 2 in the presence of a catalytic amount of 4-
dimethylaminopyridine (DMAP) to give the tert-butylsilyl
(TBS)-protected intermediate in 90% yield. Subsequently,
exposure of the intermediate to tetra-n-butylammonium ﬂuoride
(TBAF) led to the removal of the TBS protecting groups and
delivered the ﬁnal product 3 in good yield. As expected, the small
bioorthogonal alkyne tag did not aﬀect cytotoxicity, and 3 was
equally potent as compared to the original natural product
(Table 1).
With probe 3 in hand, we conducted activity-based protein
proﬁling experiments for target identiﬁcation both in the soluble
fraction of cell lysates made from MDA-MB-231 breast cancer
cells and in live MDA-MB-231 cells. Unfortunately, after in situ
click chemistry with a ﬂuorescent rhodamine azide, S2730 (see
Supporting Information), we detected no diﬀerences in labeled
proteins between negative control (lane 1), probe 3 (lane 2),
and probe 3 plus ipomoeassin F (competition; lane 3) (Figure
S2A), while an unrelated probe used as a positive control for
pulldown gave clear signals (Figure S2A, lanes 4 and 5). We
considered two possible explanations for this negative result:
ﬁrst, ipomoeassin F is not a covalent protein modiﬁer; second,
target proteins of ipomoeassin F are in low abundance. Due to
Figure 1. Structures of ipomoeassins A, D, and F.
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the dramatic loss in activity with alkene-reduced compounds, we
favored the second possibility.
In order to enrich for relatively low abundance cellular
proteins, we next synthesized the biotin-labeled analogue 5 of
ipomoeassin F by reacting the alkyne probe 3 with biotin azide
431 under chemoselective copper-catalyzed alkyne−azide
coupling (CuAAC) conditions (Scheme 1).32 The synthesis
was successful in producing biotin probe 5, which remained
cytotoxic (Table 1), showing only a∼5-fold decrease in potency.
After incubating 5 with either detergent-solubilized cell lysate or
intact cells, we used streptavidin beads to recover the biotin
probe 5-bound proteins followed by electrophoresis and silver
staining of the captured material. However, no proteins were
selectively enriched by probe 5 (Figures S3A and C, lanes 1 to
3), nor was any enrichment apparent when these samples were
probed using a ﬂuorophore-labeled streptavidin (Figure S3B,
lanes 1 to 3).
We hypothesized that if the target protein(s) of ipomoeassin F
is of relatively low abundance, then endogenously biotinylated
proteins could outcompete, and thereby mask, any positive
signal. To minimize interference from endogenously biotiny-
lated proteins, we synthesized a new biotin probe, 7 (Scheme 1),
containing a photocleavable nitrobenzene moiety,33 by coupling
the alkyne analogue 3 with the biotin azide fragment 6,
containing an o-nitrobenzyl photolabile linker, the latter
synthesized by modifying previously reported procedures31−33
Scheme 1. Synthesis of Ipomoeassin F Probes 3, 5, and 7
aReagents and conditions: (a) 4-propargyloxycinnamic acid (2), DCC, DMAP, CH2Cl2, 0 °C→ RT, overnight, 90%; (b) TBAF, THF, −10 °C, 6
h, 80%; (c) CuSO4, sodium ascorbate, CH2Cl2/t-BuOH, 3:2.
Table 1. Cytotoxicity (IC50, nM) of Ipomoeassin F, Cotransin
(CT8), and Probes 3, 5, and 7−15a
cell line
MDA-MB-231b MCF7 MCF-10A HCT116b,c
ipomoeassin F 6.3 36.4 5.3 8
CT8 −d − − 243
3 6.3 22.2 9.6 −
5 29.5 187.4 21.7 −
7 7.0 19.8 5.1 −
8 >25,000 >25,000 − 2832
9 >25,000 >25,000 − −
10 8.9 172.2 11.3 −
11 2.8 21.1 2.0 −
12 253.4 172.2 133.8 −
14 98018 256018 − 1874
15 42918 47718 − 480
aThe data were obtained from at least two independent experiments,
and the standard errors are within 20%. bSee Figure S1 for IC50
curves. cAssayed separately. d“−” indicates “not determined”.
Figure 2. SDS-PAGE images (silver staining) for aﬃnity pulldown using probe 7 with (A) or without (B) photocleavage. Red arrows indicate
speciﬁcally pulled down protein species. (C) Target validation byWestern blot with a Sec61α antibody. Ipom-F, ipomoeassin F; AP, aﬃnity pulldown.
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(see Supporting Information). Notably, the capacity of 7 to
inhibit cancer cell proliferation was close to that of parental
ipomoeassin F (Table 1), despite the large size of the appendage
at the para-position of the cinnamate benzene ring. We then
used probe 7 to label target proteins in live MDA-MB-231 cells,
performed a streptavidin pulldown on the resulting cell lysate,
and selectively released bound proteins by UV photocleavage.
When the resulting products were analyzed by SDS-PAGE,
probe 7 strongly enriched a ∼40 kDa protein and, to a lesser
extent, a second protein of ∼100 kDa (Figure 2A, lane 2, red
arrows), both of which were absent from the negative control
(Figure 2A, lane 1). In support of their bona f ide interaction with
7, these two proteins were lost when a 100-fold excess of
unmodiﬁed ipomoeassin F was included during the incubation
(Figure 2A, lane 3). Because no proteins were selectively
recovered with probe 7 when it was incubated with detergent-
solubilized (1%NP40 and 0.25% sodium deoxycholate) extracts
ofMDA-MB-231 cells (Figure S3C, lanes 1, 4, and 5), we believe
that the interaction between ipomoeassin F and its target
protein(s) may require a particular subcellular environment that
is detergent sensitive.
We next investigated whether photocleavage is essential for
the selective recovery of the two putative target protein bands
using probe 7. Strikingly, the ∼40 kDa protein was also
recovered without photocleavage. It was substantially enriched
by 7 when total streptavidin-bound products were analyzed and
was lost in the presence of excess ipomoeassin F (Figure 2B,
lanes 1−3). In contrast, an enrichment of the ∼100 kDa
component under these conditions was not apparent (Figure 2A
and B). Since photocleavage was not essential for probe 7 to
selectively recover the ∼40 kDa protein, it is very likely that the
increased linker length between the biotin moiety and the
ipomoeassin F region, but not its capacity for selective cleavage,
signiﬁcantly improved the performance of probe 7 over probe 5.
Our data also suggest that, once formed, the complex between
probe 7 and the ∼40 kDa protein is tight and can survive
detergent-containing cell lysis. This is further supported by
pulldown of the∼40 kDa target protein with low concentrations
of probe 7 (10 nM) that was outcompeted by a 5-fold excess of
ipomoeassin F (50 nM) (Figure S4A, lanes 1−3). Fluorescent
streptavidin staining suggested that a stable covalent adduct
between the∼40 kDa protein and probe 7was not formed under
our experimental conditions (Figure S3B, lanes 4 and 5). We
next submitted both the∼40 kDa protein(s) (Figure 2B, lane 2)
and the corresponding regions of the gel for the negative control
(Figure 2B, lane 1) and the ipomoeassin F competition sample
(Figure 2B, lane 3) for mass spectrometry analysis. When
spectral counts were compared, Sec61α (protein transport
protein Sec61 subunit alpha isoform 1) stood out as the only
protein that was both substantially enriched in the pulldown
with probe 7 and showed a corresponding reduction when
excess ipomoeassin F was present (Table S1). The selective
recovery of Sec61α by probe 7 was further conﬁrmed by
Western blotting (Figure 2C, cf. signals between input and AP).
To further support Sec61α as a target protein responsible for
the biological activity of ipomoeassin F, we synthesized two
inactive reference compounds, 8 and 9 (Figure 3 and Table 1),
by removing both double bonds in cinnamate and tiglate (see
Supporting Information). As predicted, pulldown experiments
with inactive biotin probe 9 revealed a loss of the ∼40 kDa
protein, even with 500 nM of 9 (Figure S4B, lanes 1 and 4).
Additionally, inactive analogue 8 was ineﬀective at competing
with probe 7 binding, even when 8 was present in 50-fold excess
(Figure S4B, cf. lanes 1 to 3). Taken together, these ﬁndings
further support the speciﬁcity of Sec61α as a primary cellular
target of ipomoeassin F.
Cell Imaging Studies. The Sec61 protein translocon plays
an essential role in translocating newly synthesized membrane
and secretory polypeptides into and across the membrane of the
ER.34,35 Sec61α forms the membrane conduit that nascent
secretory polypeptides pass through. To examine the subcellular
localization of ipomoeassin F, we performed live cell imaging
studies using three ﬂuorescent analogues, 10−12 (Figure 4),
prepared from alkyne probe 3 using CuAAC (see Supporting
Information). Both coumarin-coupled probe 10 and NBD-
coupled probe 11 retained substantial cytotoxicity, with 11
being even more potent than ipomoeassin F (see Table 1).
Unfortunately, 11 underwent photobleaching very easily and
could not be used for imaging studies. In contrast, 10 gave a
rather weak ﬂuorescent signal, presumably due to an internal
photoinduced electron transfer eﬀect combined with its shorter
excitation maximum (365 nm). To overcome these technical
limitations, rhodamine analogue 12 was synthesized from the
rhodamine azide precursor S27. Although 12 is between 5- and
40-fold less potent than ipomoeassin F depending on the cell
type analyzed, it retains substantial cytotoxicity when compared
to inactive analogues 8 and 9 (see Table 1), and we therefore
used it for our imaging studies.
Figure 3. Structures of two inactive derivatives of ipomoeassin F.
Figure 4. Structures of ﬂuorescent derivatives of ipomoeassin F.
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Subsequently, we conﬁrmed that 12 could penetrate the cell
membrane in a concentration- and time-dependent manner and
produced a strong intracellular ﬂuorescent signal. Hence, 12
stained cells within 30 min when present at 2 μM, but took >3 h
to give clear images when used at 20 nM.When cells labeled with
12 were costained with markers for either the ER or the nucleus,
it was apparent that 12 strongly labeled the ER (Figure 5), but
not the nucleus (Figure S5A). To conﬁrm the speciﬁcity of ER
labeling by 12, competition experiments were performed using
ipomoeassin F or inactive compound 8. The ﬂuorescence signal
of 12 was almost completely abolished when the cells were
preincubated for 30 min with a 100-fold excess of free
ipomoeassin F (Figure S5B), yet preincubation with compound
8 had little eﬀect (Figure S5C). The apparent ER localization of
the cellular interacting partner(s) of ipomoeassin F strongly
supports the notion that its target is Sec61α.
Pulldown from ER Microsomes. As evidenced by the
negative results from our pulldown experiments using cell lysates
prepared with detergent, we propose that the membrane
environment of the ER may be required to maintain Sec61α
in a conformation that can bind to ipomoeassin F eﬀectively. In
this regard, it would be unlikely that puriﬁed Sec61α alone could
recapitulate a direct interaction with the natural product.
However, since the biological function of Sec61α is maintained
in isolated ER microsomes22 and once prebound to probe 7 in
intact cells the resulting complex appears stable to detergent
treatment (Figures 2A and 2B), we attempted to pull down
Sec61α from puriﬁed ER-derived microsomes. After incubation
with probe 7 and detergent solubilization (1% n-dodecyl-β-D-
maltoside) to release biotin-bound proteins from the
phospholipid bilayer, only a single protein was visible after
pulldown (Figure S6A). The identity of this product was
conﬁrmed as Sec61α by Western blotting (Figure S6B). This
ﬁnding strongly supports our previous conclusionmade with live
cells, namely, that Sec61α directly interacts with ipomoeassin F.
Competition of Ipomoeassin F with Cotransin for
Binding to Sec61α. To test whether ipomoeassin F competes
for binding to Sec61α with known Sec61 ligands, such as
cotransin and mycolactone,36−38 we exploited CT7,39 a
cotransin photoaﬃnity probe that can covalently label Sec61α.
As reported earlier,36 mycolactone eﬃciently competes with
CT7 and prevents its photo-cross-linking to Sec61α (Figure 6).
A similarly potent competition was observed with ipomoeassin
F, suggesting it binds directly to Sec61α, potentially at the same
or a partially overlapping interaction site as that used by
cotransin. Ipomoeassin F competes with CT7 photo-cross-
linking with similar potency to mycolactone, consistent with its
ability to inhibit ER translocation with high potency.
In Vitro Inhibition of Protein Translocation by
Ipomoeassin F. In order to understand the consequences of
ipomoeassin F binding for Sec61α function, we used a well-
established in vitro system to study the Sec61-dependent
translocation of radiolabeled precursor proteins into ER
microsomes derived from canine pancreas.22,23 In the presence
of 1 μM ipomoeassin F, the translocation of twomodel secretory
proteins, bovine preprolactin and yeast prepro-alpha-factor, was
almost completely prevented. The blockade of protein trans-
location by ipomoeassin F was comparable to that achieved
using 1 μMmycolactone and resulted in a loss of signal sequence
cleavage and protein N-glycosylation (see Figure 7A and B; cf.
lanes 1, 3, and 4), both events speciﬁc to the ER lumen. The
unusual ability of tail-anchoredmembrane proteins to insert into
the ERmembrane independently of the Sec61 complex provides
a useful control for validating the speciﬁcity of ER translocation
inhibitors.40 The in vitro integration of two model tail-anchored
proteins bearing C-terminal N-glycosylation reporters was
unaﬀected by ipomoeassin F treatment (Figure 7C and D, cf.
lanes 1 and 3), mirroring the speciﬁcity of the Sec61-selective
inhibitor mycolactone21,22 (see also Figure 7C and D, lane 4).
Furthermore, despite the presence of carbohydrate moieties in
ipomoeassin F (see Figure 1), it has no eﬀect on the N-
glycosylation of our model tail-anchored proteins, and we
conclude that protein N-glycosylation of model substrates
provides a robust reporter for the ipomoeassin F-mediated
inhibition of Sec61-dependent protein translocation.
Known small-molecule inhibitors of Sec61-mediated protein
translocation show varying degrees of substrate selectivity,23,41
and we therefore studied the eﬀects of ipomoeassin F on the
Sec61-mediated translocation of four other classes of precursor
proteins (see Figure S7) into and across the ERmembrane using
the in vitro system outlined above.22,42 We ﬁnd that ipomoeassin
F potently inhibits the membrane insertion of representative
type I and type II integral membrane proteins that have a single
transmembrane spanning domain (Figures 7E and F). In
contrast, the compound has no eﬀect on themembrane insertion
of the single-spanning type III integral membrane protein
glycophorin C and only a marginal impact on the translocation
of the short secretory protein prepro-cecropin A (Figure 7G and
H). Interestingly, it has recently been shown that type III
membrane proteins have the unusual ability to exploit an
alternative, Sec61-independent, mechanism for ER insertion,
which relies on the ER membrane protein complex acting as an
integrase.43 On this basis, we conclude that the integration of
glycophorin C is completely refractive to ipomoeassin F (this
study) and mycolactone (see ref 42) because it can insert into
the ER via a Sec61-independent mechanism. Based on the
model membrane and secretory proteins that we have studied
here, the substrate selectivity for the ipomoeassin F-mediated
Figure 5. Cell imaging studies with ﬂuorescent probe 12 in MDA-MB-
231 cells. Rhodamine-conjugated ipomoeassin F analogue 12 (0.2 μM)
was added to cells, and after 1 h, cells were imaged to analyze
localization of 12 relative to ER staining.
Figure 6. Sheep rough microsomes were preincubated with
ipomoeassin F (Ipom-F) or mycolactone (Myco) at 10 μM.
Subsequently 100 nM photocotransin CT7 was added and samples
were photolyzed. The covalent CT7/Sec61α adduct was detected using
click chemistry to install a rhodamine-azide reporter and in-gel
ﬂuorescent scanning.
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inhibition of ER protein translocation appears remarkably
similar to that of mycolactone.42
To further investigate ipomoeassin F speciﬁcity, we used the
ER insertion of the type II membrane protein Ii (HLA class II
histocompatibility antigen gamma chain; cf. Figure 7F) to
compare the eﬀectiveness of a subset of structural variants. The
diﬀerences we observe in this in vitro assay (see Figure S8) are
strikingly similar to the variations in cytotoxicity that the same
Figure 7. Ipomoeassin F inhibits Sec61-mediated protein translocation into and across the ER in a substrate-selective manner. Phosphorimages of
membrane-associated in vitro products resolved by SDS-PAGE together with outline structures of the protein substrates generated in the presence or
absence of ipomoeassin F (Ipom-F) or mycolactone (Myco): secretory proteins (A) bovine preprolactin, PPL, and (B) yeast prepro-alpha-factor,
ppαF; tail-anchored proteins (C) C-terminally tagged Sec61β subunit, Sec61βOPG2, and (D) C-terminally tagged cytochrome b5, Cytb5OPG2; type
I single pass transmembrane protein (TMP) (E) vascular cell adhesion molecule 1, VCAM1; type II single pass TMP (F) isoform 2 (residues 17 to
232) of the short form of HLA class II histocompatibility antigen gamma chain, Ii; type III single pass TMP (G) glycophorin C, GypC; short secretory
protein (H)C-terminally taggedHyalophora cecropia preprocecropin A, ppcecAOPG2. Samples were treated with endoglycosidase H (EndoH) where
indicated to distinguish N-glycosylated (XGly) from nonglycosylated (0Gly) products. nc, signal sequence not cleaved; sc, signal sequence cleaved;
TM1, transmembrane domain 1. Proteins are of human origin unless otherwise stated.
Figure 8. Structures of ipomoeassin F analogues 13−15.
Journal of the American Chemical Society Article
DOI: 10.1021/jacs.8b13506
J. Am. Chem. Soc. 2019, 141, 8450−8461
8455
compounds display in cell-based assays (Table 1). Hence,
ipomoeassin F and the open-chain analogue 1318 (Figure 8)
strongly inhibit membrane insertion, while 1418 (Figure 8) is a
far less eﬀective inhibitor, and analogue 8 (Figure 3) has no
measurable inhibitory activity in vitro (see Figure S8A and B). Ii
membrane insertion was also used to estimate IC50 values for
ipomoeassin F (∼50 nM) and 13 (∼120 nM) (see Figure S8C
and D). The fact that we observe IC50 values in the nM range
using in vitro translocation inhibition and cell-based cytotoxicity
assays, combined with the similarity in the structure−activity
relationship observed in both systems, leads us to conclude that
the inhibitory eﬀect of ipomoeassin F on Sec61-mediated
protein translocation is most likely the principal molecular basis
for its cytotoxic activity. Furthermore, since the ER acts as the
entry point into the eukaryotic secretory pathway, our in vitro
ﬁndings predict that if cells are exposed to ipomoeassin F, their
capacity to produce and deploy membrane and/or secretory
proteins is likely compromised.
Inhibition of Protein Secretion by Ipomoeassin F in
Live Cells. Through a partnership with the National Center for
Advancing Translational Sciences (NCATS), ipomoeassin F
was included within a collection of natural products for
screening against a panel of assays to interrogate a variety of
biological pathways and assess cell-type-dependent toxicity.44
Ipomoeassin F was identiﬁed as an inhibitor of protein secretion
in two distinct quantitative high-throughput screening (qHTS)
assays using diﬀerent cell lines and secretory reporters.45 In U2-
OS human osteosarcoma cells, a protein reporter consisting of
secreted NanoLuc (secNLuc) fused to the Z mutant of alpha-1
antitrypsin (secNLuc-ATZ) was designed to monitor the
extracellular accumulation of this protein.46 Ipomoeassin F
demonstrated acute, highly potent secretion inhibition (EC50 =
∼5 nM) in U2-OS cells prior to the onset of cytotoxicity, as
assessed by decreasing cellular ATP after 24 h (Figure 9A). A
second reporter of protein secretion was also examined, using
SH-SY5Y human neuroblastoma cells expressing a secreted
Gaussia luciferase (GLuc). Ipomoeassin F inhibited secretion of
the reporter protein with a lower potency (EC50 = ∼120 nM)
than in U2-OS cells (Figure 9B), reﬂecting a potential cell-type-
dependent functional eﬀect. The secretion phenotype in cells
treated with ipomoeassin F is strongly consistent with Sec61α as
its inhibitory protein target, since most secretory proteins must
pass through the Sec61 translocon into the ER prior to traversing
the secretory pathway for extracellular secretion. The diﬀerence
in potency between diﬀerent cell lines is, again, in line with
previous observations with mycolactone.47,48
Selective Prevention of Biogenesis of Secreted
Proteins by Ipomoeassin F. To assess ipomoeassin F eﬀects
on cellular protein production, we employed a metabolic
labeling strategy. Cells were pretreated with ipomoeassin F or its
analogue 8 (Figure 3), 14, or 15 (Figure 8), for 30 min before
addition of 35S-labeledmethionine/cysteine for a further 90min.
The lack of inhibition of nascent protein biogenesis observed in
total cellular lysates and cytosolic fractions (Figure 10A and B)
demonstrates that ipomoeassin F does not acutely inﬂuence
global cellular processes such as transcription or translation and
is in line with previous observations using mycolactone.21,49 In
contrast, strong inhibition was observed for the production of
secreted proteins for cells treated with 100 nM ipomoeassin F
(Figure 10C). Importantly, ipomoeassin F inhibits the
production of most newly synthesized secretory proteins,
suggesting its mechanism of action leads to an inhibition of
biogenesis of a broad range of Sec61 substrate proteins that is
comparable to known Sec61 inhibitors such as mycolactone21,36
and apratoxin A.38,50 Ipomoeassin F analogues 8, 14, and 15 all
inhibit the production of secreted proteins less potently when
tested at 1 μM concentration. Furthermore, the rank order of
potencies with which ipomoeassin F and its analogues inhibit
protein secretion (Ipom-F > 15 > 14 > 8) correlates with their
observed cytotoxicity against HCT-116 cells (cf. Table 1 and
Figure S1C), suggesting a link between cytotoxicity and
inhibition of cellular protein secretion, as previously suggested
for other Sec61 inhibitors.36,38,51,52
HepG2 cells secrete a range of endogenous proteins, but these
products are almost completely absent following treatment with
the ER translocation inhibitor eeyarestatin I or the vesicular
transport inhibitor brefeldin A.40 To extend our studies with
HCT116 cells (Figure 10), we therefore treated HepG2 cells
with ipomoeassin F or mycolactone overnight and then followed
the fate of newly synthesized proteins by pulse chase analysis.
When the cell media was analyzed for secretory proteins, a
substantial reduction was observed for cells treated with
ipomoeassin F or mycolactone when compared to control
cells treated with DMSO or compound 8 (see Figure S9, media,
lanes 1 to 4). While the eﬀect of these Sec61 inhibitors was akin
to that of brefeldin A, treatment with the proteasome inhibitor
bortezomib had no eﬀect (see Figure S9, media, lanes 3 to 6).
When the levels of total radiolabeled proteins recovered from
the same cells were analyzed, they were directly comparable
across all treatments, conﬁrming that ipomoeassin F did not
inhibit global protein synthesis during the treatment used
(Figure S9, whole cell extract, cf. lanes 1 to 4). In fact, overnight
exposure to ipomoeassin F increases at least one prominent
cellular component (Figure S9, whole cell extract, lane 3, ∼80
kDa), perhaps reﬂecting the early stages of a cellular stress
response.51,53
Immunomodulatory Eﬀects of Ipomoeassin F. While
ultimately cytotoxic in most cell types, mycolactone has
immediate immunosuppressive eﬀects.23 Recent studies have
indicated that these eﬀects are a direct consequence of
mycolactone’s inhibitory activity on Sec61,21,36,53,54 and we
ﬁnd the eﬀects of ipomoeassin F andmycolactone are equivalent
in cell-free assays of Sec61-dependent protein translocation
(Figure 7). By blocking Sec61, mycolactone prevents the
production of both secreted proteins and membrane receptors
that are key to the generation of immune responses,21 as is
clearly illustrated by the biogenesis of CD62L, a cell surface
Figure 9. Diﬀerential eﬀect of acute ipomoeassin F treatment on
protein secretion and cell viability. Bioluminescence outputs from
secretion sensor proteins (●) and cellular viability based on total well
ATP content (○). (A) secNLuc-ATZ secretion and cell viability
measured in U2-OS cells after 24 h. (B) GLuc secretion and cell
viability measured in SH-SY5Y cells after 48 h. Error bars represent the
SEM for n = 2 or 3 replicates.
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receptor mediating naive lymphocyte homing to secondary
lymphoid organs, which is highly susceptible to mycolactone.36
In the human Jurkat T cell line, we ﬁnd that ipomoeassin F and
mycolactone downregulated CD62L expression with compara-
ble potency (Figure 11A). Likewise, they were also equivalent in
capacity to prevent interleukin (IL)-2 production by activated T
cells (Figure 11B). Together, these data suggest that, like
mycolactone,55 ipomoeassin F may display systemic immuno-
suppressive eﬀects in vivo.
Resistance of Sec61α Mutants to Ipomoeassin F
Cytotoxicity. Having established that binding of ipomoeassin
F to Sec61α potently impairs protein translocation at the ER
both in vitro and in vivo, we sought further evidence that this
interaction also underlies the cytotoxic eﬀects of ipomoeassin F
(cf. Table 1).
Chemogenetic screening has identiﬁed mutations in the
SEC61A1 gene that confer resistance to known inhibitors of
Sec61α-dependent protein translocation56 and established that
these mutations can confer resistance when engineered into a
naiv̈e cell background.37,38 We therefore compared the eﬀects of
ipomoeassin F and mycolactone on the growth of HEK293 and
HCT116 cells expressing either wild-type Sec61α or a previously
characterized point mutant of Sec61α that is resistant to
mycolactone.36,41 As previously observed using mycolactone in
HEK293 cells engineered to express mutant alleles of
Sec61α,36,41 point mutations R66I and S82P confer signiﬁcant
and dominant desensitization to ipomoeassin F in a viability
assay of HEK293 cells, yet T86M confers resistance to
mycolactone but not to ipomoeassin F (see Figure 12A and
B). Furthermore, while isolated drug-resistant HCT116 cells
carrying mutations to Sec61α of R66K and D60G were strongly
resistant to mycolactone (Figure 12D) as previously reported,51
any decrease in sensitivity to ipomoeassin F was comparatively
modest (Figure 12C). Taken together, these results strongly
suggest that ipomoeassin F and mycolactone bind to a region
similar to other known inhibitors of Sec61, but indicate that the
interaction of ipomoeassin F may be partially dependent upon
the basic side chain of residue R66 but does not require
conservation of D60 or T86.
Strong Yet Reversible Binding of Ipomoeassin F to
Sec61α. Although our SAR studies suggested that a covalent
adduct may be formed between ipomoeassin F and Sec61α, no
Figure 10.HCT-116 cells were washed twice with PBS and incubated in the presence of indicated concentrations of compounds under media lacking
methionine and cysteine for 30 min. 35S-labeled methionine and cysteine were then introduced to the media, and cells incubated for a further 90 min.
Cells were harvested by scraping into ice cold PBS and analyzed by SDS-PAGE and autoradiography. (A) The collected cells were subsequently
homogenized and analyzed by SDS-PAGE and autoradiography. (B) As for (A) but the samples are the cytosolic contents of harvested cells following
partial permeabilization with 0.15% digitonin. (C) As for (A) but the samples are from TCA-precipitated culture medium from the same experiment.
Ipom-F denotes ipomoeassin F. AprA denotes control samples treated with apratoxin A to block protein translocation into the ER. CHX denotes
samples treated with cycloheximide and chloramphenicol to inhibit total cellular protein synthesis. Cotransin CT8 is a substrate-selective inhibitor of
protein translocation into the ER.
Figure 11. Compared eﬀects of ipomoeassin F and synthetic mycolactone (A/B form) in assays of CD62L expression (A) and activation-induced
production of IL-2 (B) by Jurkat T cells. Data are means ± SEM of biological duplicates and are representative of two independent experiments.
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such adduct could be detected by ﬂuorescent streptavidin
staining of a Western blot. In order to further address the nature
of the interaction between ipomoeassin F and Sec61α, we
designed a delayed competition experiment by adding a 100-fold
excess of ipomoeassin F only after a preincubation with biotin
probe 7 (lane 4 in Figure 13A and B). Our cytotoxicity data
show that probe 7 closely resembles ipomoeassin F, and we
reasoned that if a stable covalent complex was formed between 7
and Sec61α, the later addition of ipomoeassin F would not
signiﬁcantly decrease the signal of Sec61α in an aﬃnity
pulldown. When this experiment was carried out, we observed
a time-dependent decrease in the probe 7-dependent recovery of
Sec61α in the presence of excess ipomoeassin F, such that after
60 min, the signal was substantially reduced (Figure 13A and B,
cf. lanes 2 and 4; see also Supporting Information, Figure S10,
for complete gel images).
Independently, the reversibility of ipomoeassin F activity was
also investigated using a cellular assay. This measured Sec61-
dependent production of tumor necrosis factor (TNF) by
lipopolysaccharide (LPS)-stimulated macrophage-like
RAW264.7 cells. Mycolactone’s ability to completely block
TNF production directly after a 1 h preincubation (Figure 13C,
white bars) was previously shown not to be restored following a
24 h washout,21 and this was conﬁrmed here (Figure 13C,
purple bars). In contrast, while ipomoeassin F similarly blocked
TNF production in the direct assay, after extensive washing and
24 h recovery, LPS-dependent TNF production was restored,
albeit at a reduced level. Therefore, in contrast to mycolactone,
the eﬀects of ipomoeassin F on cells are, at least partially,
reversible under these conditions.
On the basis of these results, we conclude that the binding of
ipomoeassin F to Sec61α is strong yet apparently reversible,
suggesting that it does not involve a stable covalent interaction.
■ CONCLUSIONS
Here, we report comprehensive chemical biology studies of
ipomoeassin F to understand the molecular basis for its potent
cytotoxicity. By designing and evolving our chemical probes on
an empirical basis, Sec61α was ultimately identiﬁed and
validated as a direct and physiologically relevant target of
ipomoeassin F. The results from ﬂuorescent streptavidin
staining, delayed competition in aﬃnity pulldown, and TNF-
production washout experiments indicate that ipomoeassin F is
unlikely to form a stable covalent complex with Sec61α, despite
the presence of two Michael acceptor systems in its structure
(cinnamate and tiglate, Figure 1). We therefore conclude that
the pulldown of Sec61α with probe 7 represents a successful
biotin aﬃnity enrichment of a reversible ligand−membrane
protein complex formed in live cells, most likely reﬂecting a slow
disassociation rate of ipomoeassin F from Sec61α. The binding
of ipomoeassin F to cellular Sec61α is supported by the ER
staining seen with a ﬂuorescent version of the compound, the
highly selective pulldown of Sec61α from ER-derived micro-
somes, and the ability of ipomoeassin F to compete with
cotransin for Sec61α binding.
The impact of ipomoeassin F on Sec61 function was ﬁrst
investigated in vitro, revealing a strong inhibition of protein
translocation into the ER that aﬀected secretory, type I and type
II membrane proteins. The in vitro eﬀect of ipomoeassin F
translated into potent secretion inhibition in two cellular models
utilizing independent luciferase secretory reporters. Likewise,
ipomoeassin F treatment downregulated the release of a broad
range of endogenous secretory proteins from cultured cells,
acting at a stage after their translation. At this point in our
Figure 12.Human HEK293 cells or cells engineered to express Sec61α
alleles bearing indicated point mutations were treated with increasing
concentrations of ipomoeassin F (A) or mycolactone (B), and cell
viability was assayed at 72 h with the Alamar Blue assay (mean ± SD; n
= 4 technical quadruplicates). Parental or HCT116 cells containing
mutations in Sec61A1 were seeded at 3 × 104/well in 96-well plates in
triplicate. Ipomoeassin F (C) or mycolactone (D) were added at
various concentrations with the carrier DMSO used as a control. Cell
viability wasmeasured at 96 hwith the Alamar Blue assay (mean± SEM
of n = 3 independent experiments performed in triplicate).
Figure 13. SDS-PAGE images (silver staining) for aﬃnity pulldown
using probe 7 with 0.5 h (A) or 1 h (B) competition in both regular
(lane 3) and reverse (lane 4) order. Green arrows indicate the protein
band for Sec61α. (C) TNF abundance in RAW264.7 cell supernatants
4 h after stimulation with 100 ng/mL LPS in the presence of medium
alone (ctrl), DMSO, 125 ng/mL mycolactone (Myco), or 250 nM
ipomoeassin F (Ipom-F). Cells were either preincubated for 1 h prior to
addition of LPS (“direct”) or incubated for 1 h, washed, and allowed to
recover for 24 h in complete medium before addition of LPS (“24 h
washout”). TNF was quantiﬁed by ELISA in triplicate, and the dashed
line shows the detection limit of the assay. Controls for each condition
without LPS stimulation did not reach this detectability threshold. For
each replicate, data were normalized to control levels and the mean of n
= 2 independent cellular assays is presented.
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studies, it was striking that, although structurally quite distinct,
the molecular mechanisms of ipomoeassin F and the functional
consequences of its application closely resemble those seen with
the immunosuppressive macrolide mycolactone that is released
by the human pathogenMycobacterium ulcerans.23 We therefore
studied the eﬀects of ipomoeassin F on immune cells and found
that its inhibition of membrane receptor expression and
cytokine production is comparable to that achieved with
mycolactone. Previous studies have illustrated the translational
potential of mycolactone against inﬂammatory disorders,55 but
further exploitation of mycolactone-inspired molecules has been
limited by their intrinsic structural complexity that required
extensive synthetic eﬀorts.57−62 Given that ipomoeassin variants
are easier to generate by synthetic chemistry and equally
inhibitory in cellular assays of inﬂammation, future studies of
their pharmacokinetics and therapeutic eﬃcacy against inﬂam-
matory diseases and inﬂammatory pain are an obvious area to
pursue in the future.
Lastly, we could establish an excellent correlation between the
functional Sec61 inhibition and the cytotoxic potency of
ipomoeassin F using cell lines expressing inhibitor-resistant
mutants of Sec61α. The loss of cytotoxicity we observed in
HEK293 cells expressing R66I and S82P mutants is consistent
with the notion that ipomoeassin F binds to a location that
overlaps with the interaction site for other small-molecule
inhibitors of Sec61α, most likely at or near its so-called lateral
gate.41 However, diﬀerences between ipomoeassin F and
mycolactone in response to other mutant cell lines strongly
suggest that the mode of ipomoeassin F binding to Sec61α is
distinctive from other known Sec61α inhibitors.41 The sustained
sensitivity of themycolactone-resistant T86M (inHEK293) and
D60G (in HCT116) mutant cell lines to ipomoeassin F that we
report is particularly intriguing, highlighting that ER protein
translocation can be complex63 and our current understanding is
far from complete.43
In short, we provide compelling evidence that the core α
subunit of the Sec61 translocation complex is the major target
for ipomoeassin F in a cellular context, thereby opening the way
for the exploitation of ipomoeassin F for target-based drug
discovery. More broadly, given its comparatively advantageous
synthesis, we anticipate that ipomoeassin F and its analogues/
probes will provide accessible new molecular tools that will help
our eﬀorts to fully deﬁne the molecular basis for Sec61-mediated
protein translocation at the ER membrane.
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